Santaris Pharma said this week that Soren Tulstrup has been named as the company’s new president and CEO, effective July 1.
He will replace current President and CEO Keith McCullagh, who is retiring but will remain on the company’s board.
Tulstrup previously served as vice president of global health at Merck. Before that, he served as managing director of Merck subsidiary Merck, Sharp, & Dohme Ireland. He has also held various positions at Sandoz and Abbott Laboratories.
He has an MS in economics from Copenhagen Business School and an MBA from the JL Kellogg Graduate School of Management at Northwestern University.
Lentiviral vector firm Lentigen has named Jim Meade as vice president of corporate development.
Meade will be responsible for managing partnerships, stakeholder relations, product and intellectual property portfolios, contract negotiations, and other key aspects of corporate development, Lentigen said.
He previously served as vice president of business development at Avalon Pharmaceuticals. He holds a PhD in molecular biology from the University of Texas.
Victor Ambros, a researcher at the University of Massachusetts Medical School and microRNA pioneer, has joined RXi Pharmaceuticals’ scientific advisory board.
In 1993, Ambros first published the discovery of the first miRNA and reported how the small RNA regulated gene translation in C. elegans “via an antisense RNA-RNA interaction.”